

page 56312 a notice entitled "Filing of Plat of Survey; Rhode Island." In said notice was a plat depicting the survey of the Niles Land, designated Tract No. 8, a portion of the lands held in trust for the Narragansett Indian Tribe in Washington County, Rhode Island, accepted September 23, 2003.

The official filing of the plat is hereby stayed, pending consideration of all protests.

Dated: October 29, 2003.

**Stephen D. Douglas,**

*Chief Cadastral Surveyor.*

[FR Doc. 03-27667 Filed 11-3-03; 8:45 am]

**BILLING CODE 4310-GJ-P**

## DEPARTMENT OF THE INTERIOR

### Bureau of Reclamation

#### Glen Canyon Dam Adaptive Management Work Group (AMWG), Notice of Meetings

**AGENCY:** Bureau of Reclamation, Interior.

**ACTION:** Notice of public meetings.

**SUMMARY:** The Adaptive Management Program (AMP) was implemented as a result of the Record of Decision on the Operation of Glen Canyon Dam Final Environmental Impact Statement to comply with consultation requirements of the Grand Canyon Protection Act (Pub. L. 102-575) of 1992. The AMP provides an organization and process to ensure the use of scientific information in decision making concerning Glen Canyon Dam operations and protection of the affected resources consistent with the Grand Canyon Protection Act. The AMP has been organized and includes a federal advisory committee (AMWG), a technical work group (TWG), a monitoring and research center, and independent review panels. The TWG is a subcommittee of the AMWG and provides technical advice and information for the AMWG to act upon.

*Date and Location:* The AMWG will conduct the following public meeting:

Phoenix, Arizona—January 7 to January 8, 2004. The meeting will begin at 9:30 a.m. and conclude at 5 p.m. on the first day and will begin at 8 a.m. and conclude at 2 p.m. on the second day. The meeting will be held at the Bureau of Indian Affairs—Western Regional Office, 2 Arizona Center, 400 N. 5th Street, Conference Rooms A and B (12th Floor), Phoenix, Arizona.

*Agenda:* The purpose of the meeting will be to discuss the FY 2005 budget, environmental compliance required on the temperature control device, current and potential future temperatures of

Glen Canyon Dam releases, humpback chub comprehensive plan and peer review, long-term monitoring plan development, update on GCMRC reorganization, review of AMWG Charter and Operating Procedures, experimental flows, basin hydrology, and other administrative and resource issues pertaining to the AMP.

*Date and Location:* The TWG will conduct the following public meeting: Phoenix, Arizona—November 12 to November 13, 2003. The meeting will begin at 9:30 a.m. and conclude at 5 p.m. on the first day and will begin at 8 a.m. and conclude at noon on the second day. The meeting will be held at the Bureau of Indian Affairs—Western Regional Office, 2 Arizona Center, 400 N. 5th Street, Conference Rooms A and B (12th Floor), Phoenix, Arizona.

*Agenda:* The purpose of the meeting will be to discuss the FY 2005 budget, NEPA requirements for FY 2004 and FY 2005 actions, flow modifications, update on GCMRC reorganization, Cultural Programmatic Agreement Program, FY 2004 project reviews, environmental compliance, and other administrative and resource issues pertaining to the AMP.

To allow full consideration of information by the AMWG, written notice must be provided to Dennis Kubly, Bureau of Reclamation, Upper Colorado Regional Office, 125 South State Street, Room 6107, Salt Lake City, Utah, 84138; telephone (801) 524-3715; faxogram (801) 524-3858; e-mail at [dkubly@uc.usbr.gov](mailto:dkubly@uc.usbr.gov) (5) days prior to the meeting. Any written comments received will be provided to the AMWG members prior to the meeting.

**FOR FURTHER INFORMATION CONTACT:** Dennis Kubly, telephone (801) 524-3715; faxogram (801) 524-3858; or via e-mail at [dkubly@uc.usbr.gov](mailto:dkubly@uc.usbr.gov).

Dated: October 24, 2003.

**Dennis Kubly,**

*Chief, Adaptive Management Group, Environmental Resources Division, Upper Colorado Regional Office.*

[FR Doc. 03-27628 Filed 11-3-03; 8:45 am]

**BILLING CODE 4310-MN-P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

[DEA #249]

#### Controlled Substances: Proposed Aggregate Production Quotas for 2004

**AGENCY:** Drug Enforcement Administration (DEA), Justice.

**ACTION:** Notice of proposed year 2004 aggregate production quotas.

**SUMMARY:** This notice proposes initial year 2004 aggregate production quotas for controlled substances in Schedules I and II of the Controlled Substances Act (CSA).

**DATES:** Comments or objections must be received on or before November 25, 2003.

**ADDRESSES:** Send comments or objections to the Acting Deputy Administrator, Drug Enforcement Administration, Washington, DC 20537, Attn.: DEA Federal Register Representative (CCR).

**FOR FURTHER INFORMATION CONTACT:** Frank L. Sapienza, Chief, Drug and Chemical Evaluation Section, Drug Enforcement Administration, Washington, DC 20537, Telephone: (202) 307-7183.

**SUPPLEMENTARY INFORMATION:** Section 306 of the CSA (21 U.S.C. 826) requires that the Attorney General establish aggregate production quotas for each basic class of controlled substance listed in Schedules I and II. This responsibility has been delegated to the Administrator of the DEA by § 0.100 of title 28 of the Code of Federal Regulations. The Administrator, in turn, has redelegated this function to the Deputy Administrator, pursuant to § 0.104 of title 28 of the Code of Federal Regulations.

The proposed year 2004 aggregate production quotas represent those quantities of controlled substances that may be produced in the United States in 2004 to provide adequate supplies of each substance for: The estimated medical, scientific, research, and industrial needs of the United States; lawful export requirements; and the establishment and maintenance of reserve stocks. These quotas do not include imports of controlled substances for use in industrial processes.

In determining the proposed year 2004 aggregate production quotas, the Acting Deputy Administrator considered the following factors: Total actual 2002 and estimated 2003 and 2004 net disposals of each substance by all manufacturers; estimates of 2003 year-end inventories of each substance and of any substance manufactured from it and trends in accumulation of such inventories; product development requirements of both bulk and finished dosage form manufacturers; projected demand as indicated by procurement quota applications filed pursuant to § 1303.12 of title 21 of the Code of Federal Regulations; and other pertinent information.

Pursuant to part 1303 of title 21 of the Code of Federal Regulations, the Acting

Deputy Administrator of the DEA will, in early 2004, adjust aggregate production quotas and individual manufacturing quotas allocated for the year based upon 2003 year-end inventory and actual 2003 disposition data supplied by quota recipients for

each basic class of Schedule I or II controlled substance.

Therefore, under the authority vested in the Attorney General by § 306 of the CSA of 1970 (21 U.S.C. 826), and delegated to the Administrator of the DEA by § 0.100 of title 28 of the Code of Federal Regulations, and redelegated

to the Deputy Administrator pursuant to § 0.104 of title 28 of the Code of Federal Regulations, the Acting Deputy Administrator hereby proposes that the year 2004 aggregate production quotas for the following controlled substances, expressed in grams of anhydrous acid or base, be established as follows:

| Basic class  | Proposed year<br>2004 quotas |
|--|------------------------------|
| <b>Schedule I</b>                                  |                              |
| 2,5-Dimethoxyamphetamine .....                     | 3,501,000                    |
| 2,5-Dimethoxy-4-ethylamphetamine (DOET) .....      | 2                            |
| 3-Methylfentanyl .....                             | 2                            |
| 3-Methylthiofentanyl .....                         | 2                            |
| 3,4-Methylenedioxyamphetamine (MDA) .....          | 11                           |
| 3,4-Methylenedioxy-N-ethylamphetamine (MDEA) ..... | 5                            |
| 3,4-Methylenedioxymethamphetamine (MDMA) .....     | 16                           |
| 3,4,5-Trimethoxyamphetamine .....                  | 2                            |
| 4-Bromo-2,5-Dimethoxyamphetamine (DOB) .....       | 2                            |
| 4-Bromo-2,5-Dimethoxyphenethylamine (2-CB) .....   | 2                            |
| 4-Methoxyamphetamine .....                         | 2                            |
| 4-Methylaminorex .....                             | 2                            |
| 4-Methyl-2,5-Dimethoxyamphetamine (DOM) .....      | 2                            |
| 5-Methoxy-3,4-Methylenedioxyamphetamine .....      | 2                            |
| Acetyl-alpha-methylfentanyl .....                  | 2                            |
| Acetyldihydrocodeine .....                         | 2                            |
| Acetylmethadol .....                               | 2                            |
| Allylprodine .....                                 | 4                            |
| Alphacetylmethadol .....                           | 2                            |
| Alpha-ethyltryptamine .....                        | 2                            |
| Alphameprodine .....                               | 2                            |
| Alphamethadol .....                                | 3                            |
| Alpha-methylfentanyl .....                         | 2                            |
| Alpha-methylthiofentanyl .....                     | 2                            |
| Aminorex .....                                     | 2                            |
| Benzylmorphine .....                               | 2                            |
| Betacetylmethadol .....                            | 2                            |
| Beta-hydroxy-3-methylfentanyl .....                | 2                            |
| Beta-hydroxyfentanyl .....                         | 2                            |
| Betameprodine .....                                | 2                            |
| Betamethadol .....                                 | 2                            |
| Betaprodine .....                                  | 2                            |
| Bufotenine .....                                   | 2                            |
| Cathinone .....                                    | 2                            |
| Codeine-N-oxide .....                              | 352                          |
| Diethyltryptamine .....                            | 2                            |
| Difenoxin .....                                    | 9,000                        |
| Dihydromorphine .....                              | 1,101,000                    |
| Dimethyltryptamine .....                           | 3                            |
| Gamma-hydroxybutyric acid .....                    | 10,000,000                   |
| Heroin .....                                       | 5                            |
| Hydromorphinol .....                               | 2                            |
| Hydroxypethidine .....                             | 2                            |
| Lysergic acid diethylamide (LSD) .....             | 61                           |
| Marihuana .....                                    | 840,000                      |
| Mescaline .....                                    | 2                            |
| Methaqualone .....                                 | 5                            |
| Methcathinone .....                                | 4                            |
| Methyldihydromorphine .....                        | 2                            |
| Morphine-N-oxide .....                             | 352                          |
| N,N-Dimethylamphetamine .....                      | 2                            |
| N-Ethyl-1-Phenylcyclohexylamine (PCE) .....        | 5                            |
| N-Ethylamphetamine .....                           | 7                            |
| N-Hydroxy-3,4-Methylenedioxyamphetamine .....      | 2                            |
| Noracymethadol .....                               | 2                            |
| Norlevorphanol .....                               | 52                           |
| Normethadone .....                                 | 2                            |
| Normorphine .....                                  | 12                           |
| Para-fluorofentanyl .....                          | 2                            |
| Phenomorphan .....                                 | 2                            |
| Pholcodine .....                                   | 2                            |

| Basic class                 | Proposed year 2004 quotas |
|-----------------------------|---------------------------|
| Propiram .....              | 210,000                   |
| Psilocybin .....            | 2                         |
| Psilocyn .....              | 2                         |
| Tetrahydrocannabinols ..... | 176,000                   |
| Thiofentanyl .....          | 2                         |
| Trimeperidine .....         | 2                         |

**Schedule II**

|   |             |
|---|-------------|
| 1-Phenylcyclohexylamine .....   | 2           |
| 1-Piperidinocyclohexanecarbonitrile (PCC) .....   | 10          |
| Alfentanil .....  | 200         |
| Alphaprodine .....  | 2           |
| Amobarbital .....   | 3           |
| Amphetamine .....   | 10,987,000  |
| Cocaine .....   | 186,000     |
| Codeine (for sale) .....  | 41,341,000  |
| Codeine (for conversion) .....  | 42,136,000  |
| Dextropropoxyphene .....  | 167,365,000 |
| Dihydrocodeine .....  | 681,000     |
| Diphenoxylate .....   | 716,000     |
| Ecgonine .....  | 38,000      |
| Ethylmorphine .....   | 2           |
| Fentanyl .....  | 970,000     |
| Glutethimide .....  | 2           |
| Hydrocodone (for sale) .....  | 30,622,000  |
| Hydrocodone (for conversion) .....  | 1,500,000   |
| Hydromorphone .....   | 1,651,000   |
| Isomethadone .....  | 2           |
| Levo-alphaacetylmethadol (LAAM) .....   | 2           |
| Levomethorphan .....  | 0           |
| Levorphanol .....   | 15,000      |
| Meperidine .....  | 9,753,000   |
| Metazocine .....  | 1           |
| Methadone (for sale) .....  | 14,057,000  |
| Methadone Intermediate .....  | 17,393,000  |
| Methamphetamine .....   | 2,275,000   |
| 825,000 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 1,420,000 grams for methamphetamine mostly for conversion to a schedule III product; and 30,000 grams for methamphetamine (for sale) |             |
| Methylphenidate .....   | 23,726,000  |
| Morphine (for sale) .....   | 20,762,000  |
| Morphine (for conversion) .....   | 110,774,000 |
| Nabilone .....  | 2           |
| Noroxymorphone (for sale) .....   | 99,000      |
| Noroxymorphone (for conversion) .....   | 2,900,000   |
| Opium .....   | 1,000,000   |
| Oxycodone (for sale) .....  | 41,182,000  |
| Oxycodone (for conversion) .....  | 700,000     |
| Oxymorphone .....   | 466,000     |
| Pentobarbital .....   | 18,251,000  |
| Phencyclidine .....   | 60          |
| Phenmetrazine .....   | 2           |
| Phenylacetone .....   | 0           |
| Secobarbital .....  | 1,000       |
| Sufentanil .....  | 3,000       |
| Thebaine .....  | 58,832,000  |

The Acting Deputy Administrator further proposes that aggregate production quotas for all other Schedules I and II controlled substances included in §§ 1308.11 and 1308.12 of Title 21 of the Code of Federal Regulations be established at zero.

All interested persons are invited to submit their comments and objections in writing regarding this proposal. A person may object to or comment on the proposal relating to any of the above-

mentioned substances without filing comments or objections regarding the others. If a person believes that one or more of these issues warrant a hearing, the individual should so state and summarize the reasons for this belief.

In the event that comments or objections to this proposal raise one or more issues which the Acting Deputy Administrator finds warrant a hearing, the Acting Deputy Administrator shall order a public hearing by notice in the

**Federal Register**, summarizing the issues to be heard and setting the time for the hearing.

The Office of Management and Budget has determined that notices of aggregate production quotas are not subject to centralized review under Executive Order 12866.

This action does not preempt or modify any provision of state law; nor does it impose enforcement responsibilities on any state; nor does it diminish the power of any state to

enforce its own laws. Accordingly, this action does not have federalism implications warranting the application of Executive Order 13132.

The Acting Deputy Administrator hereby certifies that this action will have no significant impact upon small entities whose interests must be considered under the Regulatory Flexibility Act, 5 U.S.C. 601 *et seq.* The establishment of aggregate production quotas for Schedules I and II controlled substances is mandated by law and by international treaty obligations. The quotas are necessary to provide for the estimated medical, scientific, research and industrial needs of the United States, for export requirements and the establishment and maintenance of reserve stocks. While aggregate production quotas are of primary importance to large manufacturers, their impact upon small entities is neither negative nor beneficial. Accordingly, the Acting Deputy Administrator has determined that this action does not require a regulatory flexibility analysis.

This action meets the applicable standards set forth in sections 3(a) and 3(b)(2) of Executive Order 12988 Civil Justice Reform.

This action will not result in the expenditure by State, local, and tribal governments, in the aggregate, or by the private sector, of \$100,000,000 or more in any one year, and will not significantly or uniquely affect small governments. Therefore, no actions were deemed necessary under the provisions of the Unfunded Mandates Reform Act of 1995.

This action is not a major rule as defined by section 804 of the Small Business Regulatory Enforcement Fairness Act of 1996. This action will not result in an annual effect on the economy of \$100,000,000 or more; a major increase in costs or prices; or significant adverse effects on competition, employment, investment, productivity, innovation, or on the ability of United States-based companies to compete with foreign-based companies in domestic and export markets.

The Drug Enforcement Administration makes every effort to write clearly. If you have suggestions as to how to improve the clarity of this regulation, call or write Frank L. Sapienza, Chief, Drug and Chemical Evaluation Section, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Telephone: (202) 307-7183.

Dated: October 27, 2003.

**Michele M. Leonhart,**

*Acting Deputy Administrator.*

[FR Doc. 03-27636 Filed 11-3-03; 8:45 am]

BILLING CODE 4410-09-P

## DEPARTMENT OF JUSTICE

### Office of Justice Programs

[OJP(OJJDP) Docket No. 1391]

#### Office of Juvenile Justice and Delinquency Prevention: Meeting of the Coordinating Council on Juvenile Justice and Delinquency Prevention

**AGENCY:** Office of Juvenile Justice and Delinquency Prevention, Office of Justice Programs, Justice.

**ACTION:** Notice of meeting.

**SUMMARY:** The Office of Juvenile Justice and Delinquency Prevention is announcing the meeting of the Coordinating Council on Juvenile Justice and Delinquency Prevention. This meeting will be open to the public.

**DATES:** Friday, November 14, 2003, from 10 a.m. to 1 p.m. (ET).

**ADDRESSES:** The meeting will take place at the U.S. Department of Justice, Office of Justice Programs, Main Conference Room, 3rd Floor, 810 Seventh Street NW., Washington, DC 20531.

**FOR FURTHER INFORMATION CONTACT:** Daryl Dunston, Program Manager, Juvenile Justice Resource Center, at: (301) 519-6473, or Karen Boston, Administrative Coordinator, Juvenile Justice Resource Center, at: (301) 519-5535. (These are not toll-free numbers.)

**SUPPLEMENTARY INFORMATION:** The Coordinating Council on Juvenile Justice and Delinquency Prevention, established pursuant to section 3(2)A of the Federal Advisory Committee Act (5 U.S.C. App. 2), will meet to carry out its advisory functions under section 206 of the Juvenile Justice and Delinquency Prevention Act of 2002, 42 U.S.C. Sec. 5601, *et seq.* Documents such as meeting announcements, agendas, minutes, and interim and final reports will be available on the Council's Web page at [ojjdp.ncjrs.org/council/index.html](http://ojjdp.ncjrs.org/council/index.html).

#### Oral and Written Comments

Requests for the opportunity to present oral comments during the meeting must be made in writing, and received no later than 12 noon, ET, on November 7, 2003. Requests should be sent to Marilyn Roberts, Designated Federal Official for the Coordinating Council on Juvenile Justice and Delinquency Prevention, by fax at: (202)

307-2093, or by e-mail, at: [robertsm@ojp.usdoj.gov](mailto:robertsm@ojp.usdoj.gov). In general, each individual or group making an oral presentation will be limited to a total time of 10 minutes.

Written comments may be submitted to the Office of Juvenile Justice and Delinquency Prevention, by fax at: (202) 307-2093, or by e-mail at: [robertsm@ojp.usdoj.gov](mailto:robertsm@ojp.usdoj.gov).

The Coordinating Council on Juvenile Justice and Delinquency Prevention expects that public statements presented at its meetings will not be repetitive of previously submitted oral or written statements.

Members of the public who wish to attend the meeting should notify the Juvenile Justice Resource Center at (301) 519-6473 (Daryl Dunston) or at (301) 519-6473 (Karen Boston), by 5 p.m., ET, on Friday, November 7, 2003. (These are not toll-free numbers.) To register for the meeting online, go to [ojjdp.ncjrs.org/council/meetings.html](http://ojjdp.ncjrs.org/council/meetings.html).

**Note:** For security purposes, photo identification will be required for admission to the meeting.

Dated: October 29, 2003.

**William L. Woodruff,**

*Deputy Administrator, Office of Juvenile Justice and Delinquency Prevention.*

[FR Doc. 03-27630 Filed 11-3-03; 8:45 am]

BILLING CODE 4410-18-P

## DEPARTMENT OF LABOR

### Occupational Safety and Health Administration

[Docket No. ICR-1218-0147 (2004)]

#### Definition and Requirements for a Nationally Recognized Testing Laboratory; Extension of the Office of Management and Budget's Approval of Information-Collection (Paperwork) Requirements

**AGENCY:** Occupational Safety and Health Administration (OSHA), Labor.

**ACTION:** Request for comment.

**SUMMARY:** OSHA requests comment concerning its proposed extension of the information-collection requirements specified by its Regulation on Nationally Recognized Testing Laboratory (29 CFR 1910.7). The Regulation specifies procedures that organizations must follow to apply for, and to maintain, OSHA's recognition to test and certify equipment, products, or material for their purpose.

**DATES:** Comments must be submitted by the following dates: